BERGENBIO TO PRESENT UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
Bergen, Norway, 4 November 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for significant unmet medical needs, is pleased to announce a poster presentation at the 63[rd] Annual American Society of Hematology (ASH) Meeting, taking place 11-14[th] December 2021 in Atlanta, GA. Prof Sonja Loges will provide an update from the Company's Phase II study (BGBC003) of bemcentinib in combination with low dose cytarabine (LDAC) in older, relapsed and refractory AML patients unfit for intensive chemotherapy. The